{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-168479","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.224288+00:00","generated_at":"2026-06-01T01:48:38.738597+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha launches $75M public offering; reports positive clinical data in Rett syndrome","bullets":["Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.","TSHA-102 in Rett syndrome shows sustained improvements in motor, hand function, and seizure reduction in two adult patients at 52 and 36 weeks.","IDMC approved dose escalation to cohort 2; first high-dose patient dosed in Q2 2024; initial data from cohort 2 expected H2 2024.","Received RMAT designation from FDA for TSHA-102 in April 2024, providing expedited development pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-168479","json":"https://secwatch.observer/filing/0001193125-24-168479.json","markdown":"https://secwatch.observer/filing/0001193125-24-168479.md","text":"https://secwatch.observer/filing/0001193125-24-168479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524168479/0001193125-24-168479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524168479/d834815d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:48:38.738597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}